Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PELI1 | Q96FA3 | 2/20 | 0.36 |
| ▸ | ESR1 | P03372 | 6/20 | 0.34 |
| ▸ | MGAM | O43451 | 3/20 | 0.33 |
| ▸ | GAA | P10253 | 3/20 | 0.33 |
| ▸ | SI | P14410 | 3/20 | 0.33 |
| ▸ | MGAM2 | Q2M2H8 | 3/20 | 0.33 |
| ▸ | MMP3 | P08254 | 1/20 | 0.33 |
| ▸ | ESR2 | Q92731 | 5/20 | 0.33 |
| ▸ | ESRRB | O95718 | 1/20 | 0.33 |
| ▸ | ESRRA | P11474 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.32 |
| ▸ | ABL1 | P00519 | 1/20 | 0.32 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.32 |
| ▸ | BCR | P11274 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10023983 | 0.80 | PELI1 (0.42) | PELI1ESR1GAAMMP3ESR2 | |
| SCHEMBL9215292 | 0.77 | ALDH1A1 (0.44) | PELI1ESR1ESR2HSD17B10 | |
| SCHEMBL10868280 | 0.76 | GRM5 (0.41) | CYP1A2CYP1B1 | |
| SCHEMBL7038780 | 0.74 | NCOA1 (0.42) | — | |
| SCHEMBL28674751 | 0.72 | MMP3 (0.58) | ESR1MMP3ESR2HSD17B10ALOX5 | |
| SCHEMBL7037593 | 0.72 | MMP3 (0.58) | ESR1MMP3ESR2HSD17B10ALOX5 | |
| SCHEMBL7036704 | 0.72 | FFAR4 (0.33) | — | |
| SCHEMBL5134382 | 0.71 | CYP1B1 (0.43) | ESR1MGAMGAASIMGAM2 | |
| SCHEMBL5030587 | 0.71 | HSD17B1 (0.52) | PELI1ESR1ESR2HSD17B10ALOX5 | |
| SCHEMBL218284 | 0.70 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030065117-A1 | Modified silicone compound, process of producing the same, and cured object obtained therefrom | NATIONAL INSTITUTE OF ADVANCED INDUSTRIAL SCIENCE AND TECHNOLOGY (JP) | 2003-04-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030065117-A1 | Modified silicone compound, process of producing the same, and cured object obtained therefrom | ORMDL3, SGMS1, HEATR1 | PELI1 2679/4885ESR1 758/4885MGAM 1219/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.